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Mapping of peptides the human genome <p>Peptides derived from protein tandem mass spectrometry data have been mapped to the human genome sequence forming an expand- able resource for the proteomic data.</p>
Abstract
A crucial aim upon the completion of the human genome is the verification and functional
annotation of all predicted genes and their protein products. Here we describe the mapping of
peptides derived from accurate interpretations of protein tandem mass spectrometry (MS) data to
eukaryotic genomes and the generation of an expandable resource for integration of data from
many diverse proteomics experiments. Furthermore, we demonstrate that peptide identifications
obtained from high-throughput proteomics can be integrated on a large scale with the human
genome. This resource could serve as an expandable repository for MS-derived proteome
information.
Background
The recent definition of the complete nucleotide sequence of
the human genome [1,2] has motivated the full annotation of
the sequence. The true promise of the human genome project,
to become the foundation for medical and biological research
benefiting human health and quality of life [3], can only be
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realized if the coding sequences are conclusively identified,
intron/exon structures are accurately described and the
potential protein products from each gene in different tissues
and cellular states are determined. Current methods for gene-
prediction provide useful information but are still limited [4].
It is not presently possible to predict all features of the
genome from its sequence alone. Therefore, the value of the
human genome sequence can be enhanced through the collec-
tion of different types of experimental data and its integration
and validation in a genomic context [5].
Current use of expressed sequence tags (EST) and full coding
DNA (cDNA) sequences is extremely helpful in achieving
complete genome annotation [6-9]. However, these data are
not sufficient to unequivocally predict which proteins (and
with what covalent structure) are expressed in a given tissue.
The complete characterization of all proteins across disease
states, tissues and stages of development can now be
addressed through experimental protein identifications gen-
erated by proteomic methods. Experiments carried out over
the past years have illustrated that peptides resulting from
proteolytic digests of complex protein mixtures can be identi-
fied in a high-throughput mode using a combination of liquid
chromatography (LC) and tandem mass spectrometry (MS/
MS) (LC-MS/MS) [10-15]. Peptides are thus useful as the cur-
rency of MS/MS-based protein identification [16]. By com-
bining a large number of experiments sampling different cell
and tissue types, the observed peptides can be mapped onto
the genome covering a significant part of its chromosomes.
Results and discussion
To begin annotating the human genome with protein-level
information, we have built PeptideAtlas. The generally appli-
cable procedure to annotate eukaryotic genomes with peptide
sequences can be applied when datasets are acquired using
different experimental protocols. In each case, sample pro-
teins were first proteolytically cleaved into peptides using the
enzyme trypsin. The resulting peptide mixture was then sub-
jected to chromatographic separation by strong cation
exchange and reverse-phase capillary chromatography. In
addition, those experiments using the ICAT (isotope-coded
affinity tag) reagent for quantification included an avidin
affinity-purification step to select peptides containing bioti-
nylated, stable-isotope-tagged cysteines [16]. The resulting
peptide pools were then analyzed by electrospray ionization
(ESI)-MS/MS. The database search program SEQUEST [17]
was used to assign the resulting MS/MS spectra to a peptide
sequence. The confidence of these peptide assignments was
evaluated using PeptideProphet [18]. All of the experimental
data products, including PeptideProphet probability scores,
are loaded into SBEAMS - Proteomics, a proteomics analysis
database built as a module under the Systems Biology Exper-
iment Analysis Management System (SBEAMS) framework.
All of the identifications above a certain probability threshold
within a specific set of experiments are extracted from the
main database tables into another set of tables containing the
attributes of each distinct peptide.
Resulting from this, 26,840 distinct peptide sequences were
identified from 224,973 spectra with identifications of a high
probability (P ≥ 0.9) of being correct. Each peptide is given a
unique and stable identifier with an eight-digit number in the
form PAp00000001. We then attempted to map the 26,840
distinct peptides to the human genome sequence using the
analysis pipeline shown schematically in Figure 1. An exam-
ple of visualizing the result in a genome browser is shown in
Figure 2 (see Materials and methods for details). The map-
ping results are summarized in Table 1. The result of this
process is stored as a freely available public resource, the
human PeptideAtlas database [19].
The current build of PeptideAtlas contains peptide sequences
identified in 52 proteomic experiments in which proteins
were extracted from a particular cell or tissue type, digested
with trypsin and analyzed with a mass spectrometer. The 52
proteomic experiments comprised 14 published as well as 38
unpublished human datasets from various cell types such as
T cells, B cells, lymphocytes, lymphoblasts, hepatocytes,
intestinal cells, hepatoma cells and others. The 14 published
datasets contain 47% of the distinct peptides in PeptideAtlas.
A full listing of all the experiments and samples currently in
PeptideAtlas can be found at the project website [19]. The raw
data for all published datasets is also provided in a repository
there.
The cumulative number of distinct peptides as a function of
the addition of identified spectra (with P ≥ 0.9) in the atlas is
shown in Figure 3. As most of the observable peptides in the
proteome are matched with genes, the curve is expected to
saturate and adding additional data will yield few new
matched genes. However, the current behavior is still com-
pletely linear, with approximately 1 in 10 identified spectra
contributing a previously uncataloged peptide. Each data
point represents an added experiment; the experiments are
presented approximately in chronological order of data col-
lection. Among the 52 experiments, there is clearly great var-
iability in the total number of identified spectra contributed
as well as new distinct peptides contributed. A repeated, com-
plex-sample experiment might yield many new spectra but
few new distinct peptides, while a new sample of a type not
previously analyzed might yield relatively few spectra but
most of these might contribute a new distinct peptide.
Applying our pipeline described in Materials and methods,
25,754 of the 26,840 distinct peptides in PeptideAtlas were
mapped to 9,747 (28.6 %) of the 34,091 human Ensembl pro-
teins (version 22.34d.1, 2004-06-02). These proteins repre-
sent unique proteins or splice forms from 6,423 genes (27%)
of human genes in Ensembl.http://genomebiology.com/2004/6/1/R9 Genome Biology 2004,     Volume 6, Issue 1, Article R9       Desiere et al. R9.3
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Some peptides have indistinguishable, perfect protein
sequence matches to multiple proteins. These proteins are
typically paralogs (protein families), protein isoforms or
repeated protein domains in the human genome. We identi-
fied 3,718 proteins unambiguously by one or more 'discrete
peptides' - peptides that map uniquely to a single protein - in
the current build of PeptideAtlas. Those peptides are marked
in the genome browser as 'discrete peptide'. 'Degenerate pep-
tides' that map to several protein isoforms are also used to
identify proteins. It would thus be more accurate to state that
a product of a certain gene, rather than a certain protein, has
been identified [20-22]. Moreover, the experimental data
from those degenerate peptides generally do not allow differ-
entiation between the sequence alternatives that exist in
Ensembl. In fact, not all splicing variants that are in Swiss-
Prot are also present in Ensembl and, therefore, it is impossi-
ble to ascertain the number of unambiguous identifications at
the moment. This limitation underscores the requirement for
mapping large-scale proteomic data to the human genome,
such as presented in this report to aid in the generation of
unambiguous sequence databases.
A significant number of distinct peptides (1,086), assigned by
SEQUEST/ProteinProphet from over 5,000 MS/MS spectra,
could not be mapped to Ensembl database version 22.34d.1.
These peptides were identified by SEQUEST searches against
the IPI database [23] or ABCC non-redundant protein data-
base (NCI) [24]. These peptides are of special interest as they
often document interesting biological phenomena such as
single-nucleotide polymorphisms (SNPs) and novel splice
variants, demonstrating the need for annotating the human
g e n o m e  s e q u e n c e  w i t h  h i g h -quality experimental data
obtained from expressed proteins. The existence of these
sequences also illustrates the flux in the genome annotation
and sequence databases. For example, in Ensembl version
18.34.1, only 92% of genes from the previous build were
transferred across to the new build. The missing 8% were pre-
dominantly inappropriate protein-coding genes coming from
Analysis pipeline for the annotation of the human genome with high-quality peptide sequences derived from high-throughput MS analysis of biological  samples Figure 1
Analysis pipeline for the annotation of the human genome with high-quality peptide sequences derived from high-throughput MS analysis of biological 
samples.
Peptides Sample Proteins
Digestion
From peptides to genome annotation
Spectrum      Peptide     Probability
Spectrum 1   LGEYGH         1.0
         …                 …                …
Spectrum N   EIQKKF          0.3
BLAST
protein
database
Statistical
filtering
LC-MS/MS
Database
search
20 40 60 80 100120
Extraction
Mass spectrum
Peptides
Visualization
PeptideAtlas database Genome browser
Map to
genome
 Peptide            …  Chrom  Start_Coord   End_Coord …
PAp00007336    …    X          132217318     132217368   …
         …             …    …          …                        …                       …R9.4 Genome Biology 2004,     Volume 6, Issue 1, Article R9       Desiere et al. http://genomebiology.com/2004/6/1/R9
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large-scale cDNA projects, which have a number of artifactual
errors, or from chimeric cDNA clones from cancer cell lines.
Experimentally observed, unmapped peptides are an ideal
source of information for refining genome assembly and gene
prediction.
The absence of Ensembl matches does raise the question of
whether these peptides are false positives or whether real pro-
teins are missing in the Ensembl database. When these pep-
tides were investigated in more detail it was found that nearly
100 were identified 10 or more times in several different
Visualization of PeptideAtlas peptide entries in the Ensembl DAS browser as a separate track at the top called PeptideAtlas, displayed as light blue  rectangles Figure 2
Visualization of PeptideAtlas peptide entries in the Ensembl DAS browser as a separate track at the top called PeptideAtlas, displayed as light blue 
rectangles. The Ensembl genome browser, here showing 10 kilobases (kb) on chromosome 12, can be used to zoom into the genome down to the 
nucleotide level. A light blue line connects peptides that map on intro/exon boundaries. Details about the peptide, including its unique identifier, peptide 
sequence, best PeptideProphet probability [22] (marked SCORE) and PeptideAtlas hyperlink are displayed.
Table 1
Summary of PeptideAtlas results
Human Drosophila
Ensembl version 22.34d.1 2004-06-02 19.3a.2, 2003-07-01
Ensembl gene predictions 23758 13525 from Release 3.1 FlyBase
Ensembl gene transcripts 34091 18289
PeptideAtlas version FullHumanEns22APD0704P0.9 Fly 2
PeptideAtlas peptides 26840 4406
Number of experiments 52 3
PeptideProphet probability threshold 0.9 0.9
PeptideAtlas mapped peptides 25754 4406
PeptideAtlas mapped proteins 9747 3107
PeptideAtlas mapped genes 6423 1876
Percentage of the genome 27 % 14 %http://genomebiology.com/2004/6/1/R9 Genome Biology 2004,     Volume 6, Issue 1, Article R9       Desiere et al. R9.5
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Genome Biology 2004, 6:R9
experiments, and that many had protein sequence matches
for Swiss-Prot entries. They are therefore likely to be true
peptide attributions. For example, peptide PAp00000363
(AGKPVICATQMLESMIK) was identified 626 times at differ-
ent charge states and with different mass modifications in 22
distinct experiments and mapped to KPY1_HUMAN, a pyru-
vate kinase M1 isozyme. Interestingly, the protein appears to
have a likely SNP, which mutates the valine present in the
Ensembl genome sequence to the isoleucine observed in
PAp00000363.
The 9,747 mapped proteins represent 28.6% of the predicted
human proteome in Ensembl version 22.34d.1. The distribu-
tion of peptide matches to these proteins (Figure 4) revealed
coverage of all chromosomes. Void areas were observed in the
centromere region of chromosome 1 and the telomere regions
of chromosomes 13, 14 and 15. These missing regions repre-
sent the unsequenced parts of human chromosomal hetero-
chromatin structures and are therefore expected to be devoid
of peptide matches. Very few peptides were observed mapped
to chromosome Y.
The development of PeptideAtlas and a method for mapping
observed peptides to the genome allows us to determine the
distribution of multiple peptide hits to specific proteins and
the distribution of peptide sequences that are present in mul-
tiple proteins. Also, in some cases splice junctions and gene
boundaries could be confirmed. Our method allows us also to
identify peptides corresponding to abundant proteins such as
actin, elongation factor and glyceraldehyde-3-phosphate
dehydrogenase, which are commonly identified in high-
throughput LC-MS/MS experiments. These proteins are
products of housekeeping genes, which are expressed most of
the time in almost every tissue [25], or are structural proteins
which are also known to be abundant in cells.
The identification of proteins that are specific to a given cell,
tissue or disease state allows for the selection of marker pro-
teins. The knowledge of a single marker, or a set of marker
proteins, is crucial for the development of new strategies for
rapid protein analysis and quantitative proteome profiling
[16,26]. In PeptideAtlas we identify proteins to which two or
more peptides map. In fact, for some proteins, 100 or more
peptide matches were determined. These proteins were often
unusually large in size and contained many exons. Examples
of such proteins include the 1,462-amino-acid alpha-2-mac-
roglobulin precursor (ENSP00000323929), which was
matched by 161 peptides, or the 4,126-amino-acid DNA-
dependent protein kinase catalytic subunit
(ENSP00000313420) matched by 90 peptides (Figure 5), the
2,472-amino-acid spectrin alpha-chain protein
(ENSP00000238302) with 102 peptides, and cytoplasmic 2
actin (ENSP00000331514) with 127 peptides.
We also identified peptides whose amino-acid sequence is
shared by members of protein families or shared domains
among proteins in the genome. Peptides were matched to all
identical sequences in all proteins. Multiple hits were possible
and the resulting peptides were called degenerate peptides
[22], in contrast to discrete peptides that matched one pro-
tein uniquely. For example, peptide PAp00001228 (CNGV-
LEGIR) matched to 26 proteins in the myosin family and
peptide PAp00025728 (HCQLAIR) mapped to 23 proteins.
Furthermore, our method was able to confirm intron/exon
boundaries by identifying peptides that spanned these
regions in a gene. We identified 4,800 intron/exon boundary-
spanning peptides, corresponding to 2% of the splice junc-
tions in the human Ensembl database, experimentally con-
firming specific intron/exon junctions. In most cases, these
boundaries were already known to exist from cDNA informa-
tion. However, using peptide information we were able to
specifically confirm those boundaries on the level of
expressed proteins. In one case (Figure 6) we observed a
peptide confirming a skipped exon. This event was previously
proposed to occur during expression of the A-type lamins in
the lung adenocarcinoma cell line GLC-A1 [27]. The presence
of some lamin A10 isoforms can easily be overlooked owing to
their relatively low abundance. This new peptide information
confirms the existence of this splice variant and shows that
low-abundance proteins can be detected through the pro-
teomics technologies described in this paper.
Cumulative number of distinct peptides as a function of the addition of  more good spectra (identified with P ≥ 0.9) Figure 3
Cumulative number of distinct peptides as a function of the addition of 
more good spectra (identified with P ≥ 0.9). Eventually the pattern is 
expected to show saturation, as most observable peptides will have been 
cataloged. However, at present there is no evidence of saturation and 
around 100 new peptides are still cataloged per 1,000 identified spectra 
added.
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The need for public proteomics data repositories is recog-
nized [28] and we intend PeptideAtlas to become a growing
database and public resource. We have structured the system
in a way that allows scientists to submit their own MS data for
incorporation into PeptideAtlas, thus increasing the number
of experiments and identified peptides. Naturally, to be useful
for the project, inclusion of third-party data is dependent
upon data compatibility and consistent data quality. Conse-
quently, only data with accurate statistical measures of confi-
dence computed by, for example, PeptideProphet, or another
published and tested statistical algorithm, will be included.
Datasets for which such statistical analyses have been per-
formed can be submitted for incorporation following the pro-
cedure detailed at the PeptideAtlas website. Alternatively,
data contributors can submit raw MS/MS data directly. This
information should preferably be formatted into mzXML [29]
or mzData (HUPO Proteomics Standards Initiative) which
are open file formats for the representation of MS data. Other
traditionally used data formats are accepted as well.
This data will then be searched by the PeptideAtlas curators
using SEQUEST to correlate MS/MS spectra of peptides with
amino-acid sequences using protein databases such as IPI,
and the results will be further analyzed with PeptideProphet.
An effort to add support for additional search engines is
underway. This procedure will ensure the highest degree of
consistency for the data in PeptideAtlas. In the future, the
pipeline in general and the data submission process in partic-
ular, can be further improved and make compliant with the
community accepted statistical data-validation standards
and data file formats when such standards emerge [30].
Please see the submission section on the PeptideAtlas web-
site for the most up-to-date submission methods and curator
contact information. With an increasing number of included
peptides, the utility of the resource will improve, as increasing
numbers of genes, exons, transcripts and variant transcripts
in many tissues and developmental stages will be verified on
the protein level.
All MS/MS spectra are stored in the SBEAMS - Proteomics
database, from which PeptideAtlas is derived. While at
present it is not possible easily to access the MS/MS spectra
starting from the public PeptideAtlas interface, this possibil-
ity could be added in the future. All spectra for published
experiments are available in the mzXML files in the reposi-
tory. Access to raw spectra can be beneficial for many appli-
cations not related to the main purpose of PeptideAtlas.
Furthermore, because peptide modifications (for example,
phosphorylation) are stored, this information could be dis-
played as well.
It is well understood and discussed in the literature [21] that
all large-scale datasets obtained using high-throughput
methods inherently contain a certain fraction of false-positive
data. Thus, estimation of false-positive error rates is a very
important but often challenging task. One significant advan-
tage of the high-throughput pipeline implemented in this
work is that computed peptide probabilities (here produced
by PeptideProphet) allow estimation of the upper bound
(most conservative estimate) of the false-positive identifica-
tion error rates for any dataset submitted to PeptideAtlas. As
the main purpose of PeptideAtlas is to map peptide identifi-
cations to the genome, the most relevant estimate of the false-
positive error rates is the one at the level of distinct peptide
assignments that have a defined mapping to Ensembl.
Initial datasets of peptide assignments to MS/MS spectra,
obtained by searching acquired MS/MS spectra using the
database search program SEQUEST, were statistically vali-
dated using the computational tool PeptideProphet. For each
peptide assignment to an MS/MS spectrum, PeptideProphet
computes a probability of its being correct, based on its data-
base search scores, difference between the measured and the-
oretical peptide mass, the number of termini consistent with
the type of enzymatic cleavage used, the number of missed
cleavage sites and other factors. Probabilities computed by
PeptideProphet have been shown to be accurate in the entire
probability range and, therefore, can be used to compute the
false-positive identification error rate (fraction of all identifi-
cations passing the filter that are incorrect) resulting from fil-
tering each dataset using any minimum computed peptide
probability threshold [18]. The false-positive identification
error rates for the combined dataset of peptide assignments
(all 52 experiments) filtered using minimum probability
thresholds 0.7, 0.9, 0.95 and 0.99 are shown in Table 2.
To assess the effect of using a particular probability threshold
on the number of peptides in the atlas, we ran the PeptideAt-
las pipeline using probability thresholds P ≥ 0.7, 0.9, 0.95 and
0.99. Decreasing the probability threshold increases the
number of peptides, both correctly and incorrectly identified,
and the corresponding proteins (Table 2). The most stringent
threshold of P ≥ 0.99 produced 21,030 peptides with protein
sequence matches (4,845 protein identifications), almost
8,400 fewer than the lowest threshold of 0.7 (2,252 fewer
protein identifications). The P ≥ 0.9 threshold yielded 25,754
Distribution of PeptideAtlas peptides on the human genome Figure 4 (see previous page)
Distribution of PeptideAtlas peptides on the human genome. Each chromosome is described by three columns. The left-most column shows a 
chromosome's standard banding. The right-most column presents a histogram of the mapping of peptides to chromosomal regions; a line's length 
represents the number of peptides mapped to a chromosomal region. The central column indicates the over/under representation of peptides in a given 
region. Green regions represent more mapped peptides than expected at uniform random; red regions indicate fewer mapped peptides than expected at 
uniform random.R9.8 Genome Biology 2004,     Volume 6, Issue 1, Article R9       Desiere et al. http://genomebiology.com/2004/6/1/R9
Genome Biology 2004, 6:R9
View of the DNA-dependent protein kinase catalytic subunit PRKDC gene (ENSG00000121031), which is matched by 90 distinct peptides in PeptideAtlas Figure 5
View of the DNA-dependent protein kinase catalytic subunit PRKDC gene (ENSG00000121031), which is matched by 90 distinct peptides in PeptideAtlas.http://genomebiology.com/2004/6/1/R9 Genome Biology 2004,     Volume 6, Issue 1, Article R9       Desiere et al. R9.9
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peptides with protein sequence matches at an estimated
false-positive rate of less than 7%, and we selected this as an
acceptable level for the default PeptideAtlas. The number of
false-positive identifications could be reduced by selecting a
higher threshold; however, a significant number of correct
peptides and proteins would then also be eliminated. The
additional peptides resulting from the low-probability
threshold were valuable for adding additional peptide
evidence in combination with higher-probability peptides
corresponding to the same protein (peptides corresponding
to proteins to which other peptides correspond are more
likely to be correct than their probability value indicates
[22]). We provide at our website the option for users to
browse or download versions of the Atlas generated with the
other  P  thresholds, which might be useful for some
applications.
To validate our approach for general use in eukaryote
genomes, we have extended our methods to peptides
obtained from Drosophila melanogaster LC-MS/MS experi-
ments. We collected data obtained from cytoplasmic, nuclear
and membrane fractions derived from a Drosophila S2 Sch-
neider cell line. The resulting 4,406 different peptides with P
> 0.9 were compared to the 18,289 proteins (Ensembl fly
database version 18.3a.1, 2003-07-01) using the same pipe-
line as described for human. From the fly, 3,107 proteins
could be validated, representing 1,876 (14%) of the fly's genes.
These results show that our method could easily be adapted to
other organisms, thus opening up the way for comparative
proteome-level evaluations of eukaryotic organisms.
Conclusions
We have annotated the human genome with protein evidence
for nearly 10,000 proteins. Although this number only repre-
sents a fraction of the genome and still contains some errone-
ous identifications, it is a first step towards the final goal: to
fully annotate eukaryotic genomes via validation of expressed
proteins. PeptideAtlas provides a method and a framework to
accommodate proteome information generated by high-
throughput proteomics technologies and is able to efficiently
disseminate experimental data in the public domain. Its sig-
nificance continues to grow as more data are submitted.
Example of peptides confirming a case of alternative splicing of the lamin A/C gene (LMNA) Figure 6
Example of peptides confirming a case of alternative splicing of the lamin A/C gene (LMNA). PAp00038023 was identified as part of protein 
ENSP00000310687 from the SiHa human cell line experiment. PAp00042742 was identified as part of protein ENSP00000292304 from a human B-cell 
experiment.R9.10 Genome Biology 2004,     Volume 6, Issue 1, Article R9       Desiere et al. http://genomebiology.com/2004/6/1/R9
Genome Biology 2004, 6:R9
Moreover, PeptideAtlas also allows one to address the impor-
tant question of how big the human proteome is. Due to the
technical limitations of current proteomics technologies, it is
not possible yet to determine the complete proteome in one
experiment. However, if the data from diverse experiments,
using different cellular compartments and enrichment meth-
ods were combined, the determination of the complete pro-
teome could eventually be achieved. PeptideAtlas offers the
framework to answer this question accurately and to deter-
mine the size of the complete human proteome using pooled
experimental data. Furthermore, PeptideAtlas provides a
resource for the development of new avenues of research. The
dataset will provide a rich source of data for computational
scientists to develop and test new algorithms for proteomic
analysis, gene discovery and splice-variant prediction.
The methods described here, combined with the ever-increas-
ing power of proteomics and bioinformatics technologies, will
facilitate the determination or characterization of protein-
coding genes, their features, and their processing and expres-
sion in relationship to the sequence of the human genome,
thus contributing significantly to our understanding of
genome structure.
Materials and methods
Pipeline
The assembly of experimentally derived distinct peptides is
mapped to the human genome in the following way. First, we
use BLAST [31] to match the peptides to the Ensembl human
protein database. The Ensembl database project [32] pro-
vides a bioinformatics framework to organize biology around
the sequences of large genomes and, furthermore, extensive
resources and visualization options as well as remote access
to the underlying relational databases [33]. The human
genome sequence (release 22.34d.1, 2004-06-02) contains
23,758 genes and 34,091 gene transcripts. Second, complete
matches, spanning each peptide's complete length, were used
to determine human chromosomal coordinates. The method
for retrieving chromosomal coordinates within the human
genome accounts for splice junctions; in cases where a pep-
tide maps onto a splice junction, it is projected to both parts
of the chromosome, generating multiple sets of coordinates.
Third, the results are loaded into a relational database. This
database schema (available at the project website [19]) is able
to accommodate data for different PeptideAtlas builds, for
different organisms or different reference protein sequence
sets as starting material and is thus extremely versatile.
Fourth, visualization of the results was achieved using the
Distributed Annotation System (DAS) (Figure 2) in conjunc-
tion with the Ensembl database. DAS allows sequence anno-
tations to be decentralized among multiple third-party
annotators and integrated on an as-needed basis by the
Ensembl genome browser [34].
Data collection
LC-MS/MS analysis was performed on LCQ, Ion-trap
(Thermo Finnigan LCQ) and Q-Tof (Micromass Waters)
instruments.
To estimate the false-positive error rate on the level of distinct
peptide identifications, we first note that there is an almost
10-fold difference between the number of peptide assign-
ments to MS/MS spectra and the number of resulting distinct
peptide identifications. This can be explained by the fact that
many peptides were sequenced multiple times, with some of
the most abundant peptides sequenced more than 1,000
times (for example, peptides PAp00004784, PAp00003568,
PAp00026910). While many correct peptide assignments to
MS/MS spectra represent the same peptide sequence, the
majority of incorrect peptide assignments are expected to be
single identifications. As a result, the false-positive error rate
on the level of distinct peptides is higher than that on the level
of peptide assignments to MS/MS spectra.
Second, it should also be taken into account that a considera-
ble fraction of all distinct peptides did not match any Ensembl
entry. This is due to the fact that MS/MS spectra were
searched against larger databases, such as human IPI, which
contained a number of protein sequences not present in
Table 2
Comparison of different probability thresholds that were applied to the MS results
Probability ≥ 0.70 ≥ 0.90 ≥ 0.95 ≥ 0.99
Total number of passing spectra 245724 224793 211674 179410
Peptides 31290 26840 25022 21598
Distinct peptides with protein sequence matches 29393 25754 24172 21030
Number of mapped proteins 11612 9747 9016 8134
Number of simple reduced proteins 7097 5826 5383 4845
False-positive estimate MS/MS spectra 2.4% 0.9% 0.05% 0.01%
False-positive estimate with protein sequence matches <16% <6% <3% <0.8%http://genomebiology.com/2004/6/1/R9 Genome Biology 2004,     Volume 6, Issue 1, Article R9       Desiere et al. R9.11
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Ensembl. The fraction of all distinct peptide identifications
that did not map to any Ensembl entry can be estimated using
information provided in Table 2. Among peptides with prob-
ability of being correct of 0.99 or greater, only 2.6% of all dis-
tinct peptides did not map to any Ensembl sequence. The
fraction of unmapped distinct peptides increases to 8.3%
among peptides in the 0.95-0.99 probability range, 12.9% in
the 0.9-0.95 range and 18.2% in the 0.7-0.9 range, reflecting
the increase in the number of incorrect peptide identifica-
tions among peptides with lower probabilities. Thus, one can
estimate that at least 18.2% of all incorrectly identified pep-
tides did not map to any entry in Ensembl.
The false-positive error rate among distinct peptides that
mapped to Ensembl (peptides with protein sequence match)
can then be estimated to be not higher than the maximum
possible number of distinct incorrect peptide identifications
that have protein sequence matches (computed by multiply-
ing the total number of peptide assignments to MS/MS spec-
tra by the corresponding false-positive error rate and
applying an 18.2% correction to account for peptides with no
mapping to Ensembl) divided by the total number of peptides
with protein sequence matches. The corresponding estimates
are 16%, 6%, 3% and 0.8% in the case of minimum-probabil-
ity thresholds 0.7, 9, 0.95 and 0.99, respectively (Table 2). It
should be noted that these are conservative (upper bound)
estimates and the actual error rate may be significantly
smaller.
Population of the database
The PeptideAtlas pipeline begins with the download of the
Ensembl human protein database from [35]. Release
22.34d.1 (2004-06-02) was used here. PeptideAtlas peptides
were then searched against the human proteins using BLAST
with the following parameters adapted for searching small
peptides [31]: -E 1 -W 2 -M PAM30 -G 9 -e 10 -K 50 -b 50 -F
F. The BLAST results were then filtered for identical matches
and mapped into chromosomal coordinates using
Bio::EnsEMBL and Bioperl [36] Perl modules. The results are
uploaded into the PeptideAtlas database and then the
Ensembl genome browser. The PeptideAtlas database can
handle different PeptideAtlas builds, different organisms and
different versions of underlying genome data for maximum
flexibility.
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